TCTAP 2023 ACS with or without Cardiac Support Devices

Hironobu Kikuchi, MD The University of Tokyo Hsopital



Disclosure

The author have no financial conflicts of interest todisclose concerning the presentation



Features of ACS


- Rapidly progressive ischemia.
- \rightarrow May not spend enough time on procedure.
- Difficulty of the procedure is unknown or well considered.
- \rightarrow Unexpected difficulties or complications can arise.
- Unlike elective cases, there may be a lack of staff and limited equipment available.
- Hemodynamics may be disrupted or may be disrupted during the procedure →need cardiac support devices

81F, CPAOA

One of our severest cases of ACS with cardiac support devices

- 81F, cardio-pulmonary arrest on arrival \rightarrow resuscitated
- LMT/LAD/LCx 99%, RCA: no stenosis
- ECMO→PCI→ECMO+IABP
- Rota to LMT-LAD, LMT-LAD
- After stabilizing CHF, CABG×2(LITA-LAD, SVG-D1-PL)
- Now 18 months after the event,

she walks to outpatient clinic





ACS without cardiac support devices


- Rather easy cases. Low risk score by AHA/SYNTAX/GRACE etc.
- Hemodynamics are stable.
- Must keep in mind the possibility of hemodynamic breakdown during procedure.



ACS without cardiac support devices (in high risk cases without shock)

Is it safe or not safe?

 ACS without cardiac support devices had low 30 day mortality not when complicated by shock.



Am J Cardiol . 2021 Nov 1;158:37-44.

2585 patients(3914 lesions) In-hospital and 30 day mortality: 2%(UAP), 2.1%(NSTEMI), STEMI(4.7%)


Considering Cadiac Support Devices

Risk score

- ACS-MCS score
- Shock cases due to ACS with Mechanical Cardiac Support(IABP, Impella, ECMO)
- Higher score, higher mortality
- Risk stratification tool
- May help decision

ACS-MCS Mortality Risk Score

- Age ≥ 60
 1 point
- Lactate ≥ 2.5 mmol/L 1 point
- SCAI CS stage E 1 point
- AKI 1 point



ACS with cardiac support devices

When you consider introducing devices

- Hemodynamics are disrupted. (CPA/CPR cases, Forrester IV, low EF) or may disrupted.
- Extensive ischemia. (LMT, multi vessel disease, proximal or diffuse LAD; preventive use.)
- \rightarrow accurate risk assessment is needed.
- Non coronary complications (valvular disease, cardiomyopathy)




Common cardiac support devices used during ACS PCI

- IABP (Intra Aortic Balloon Pumping)
- Impella
- ECMO (Extracorporeal Membrane Oxygenation)
- Recently, Implella use is increasing

Features of each devices

IABP/IMPELLA/ECMO



Intra-Aortic Balloon Pump

Advantages:

- Ubiquitous available in most cardiac catheterization laboratories throughout the world
- Ease of percutaneous implantation
- Available in 7Fr, 7.5Fr, and 8Fr catheter sizes minimizing threat of vascular complications
- Contemporary systems use fiber-optic technology negating risks associated with a fluid-filled pressure line
- Newer systems calibrate automatically in vivo accelerating the time to effective diastolic augmentation
- Range of balloon sizes available to accommodate patients of all heights
- Larger volume balloons displace more blood providing enhanced diastolic augmentation and systolic unloading

Potential disadvantages:

- Can only supplement cardiac output by up to 0.3-0.5 I/min and requires a degree of native cardiac output to function
- Relies on synchronization with the cardiac cycle so circulatory support may not be reliable with dysrhythmia
- Risk of balloon displacement, rupture, leak, or entrapment
- Twisting/kinking of and clot formation in the pressure line or catheter
- Small but tangible risk of aortic dissection or rupture
- Systemic embolization (e.g. cholesterol, helium)
- Stroke
- Infection
- *Lower limb ischemia +
- *Hemolysis +
- *Bleeding at insertion site +



Impella

Advantages:

- Can augment cardiac output by 2.5 l/min [impella 2.5] to 4 l/min (impella CP^{**}/cVAD)
- Can be used to support the circulation for up to 7 days
- Does not require a stable cardiac rhythm or native cardiac output/blood pressure signal for optimal function – the device does, however, require adequate filling of the left ventricle for optimal function

Potential disadvantages:

· Not universally available

- Requires 12-14Fr catheters for implantation thus increasing the risk of vascular complications
- Non-pulsatile flow
- Risk of displacement of inflow from the left ventricle to the aorta
- Insufficient flow to the periphery in larger patients (>100 kg body mass)
- Systemic embolization
- Stroke
 Infection
- *Lower limb ischemia ++
- *Hemolysis ++
 *Bloading at insertion site.
- *Bleeding at insertion site ++



But how to choose each devices?

cardiopulmonary resuscitation • Relatively complex post-implantation management

for implantation of a 21Fr cannula

· Implantation cannot be performed during

· Relatively long implantation time

 Risk of left atrial cannula tip displacement into the right atrium causing profound desaturation

· Does not require a stable cardiac rhythm or native

Requires specific expertise with transseptal punctures

cardiac output/blood pressure signal for optimal

- 17Fr femoral arterial cannula increases risk of vascular complications
- Systemic embolization
- Stroke

function

Potential disadvantages:

Not universally available

- Infection
- *Lower limb ischemia +++
- *Hemolysis ++
- Bloeding at insertion site ++

JACC Cardiovasc Interv . 2015 Feb;8(2):229-244.


*Denotes relative grading between all three devices.

IABP-SHOCK II trial

• AMI with shock patients

(1:1 with IABP/without IABP)


- randomized, prospective, open-label, multicenter trial
- Primary endpoint: 30 days mortality
- No significant differences between IABP group and control group (relative risk 0.96; 95%; P=0.69)



N Engl J Med. 2012 Oct 4;367(14):1287-96.

ECPELLA better than ECMO only


- Shock treatment study (not limited to ACS: AMI 59.3%/63.5%)
- Multicenter, international cohort
- ECMO+Impella had lower rate or death from any cause.



Circulation. 2020 Dec;142(22):2095-2106.

ACS with shock; ECMO+IABP or ECMO+Impella?

- ECMO+Impella may improve overall survival of patients with shock due to ACS.
- Limitation: single center study, not randomized, small number of cases(without CPA: 40, with CPA 24)



STEMI-DTU pilot trial

- Unloading(Impella CP) before PCI may be better than PCI before unloading
- Small size, pilot study
- 30 min. delay of PCI in U-DR group
- Not statistically significant but first proved feasibility of Unloading first strategy.

<u> </u>	50 patients enrolled rand	domized and Unloaded	
	U-IR (n=25)	U-DR (n=25)	
	No CMR Completed {n=5} 1 expired 1 metallic prosthesis 2 large body mass index 1 outside time window (n=20) No CMR Completed (n=1) 1 outside time window	No CMR Completed (n=4) 1 expired 2 claustrophobic 1 chronic kidney disease (n=21)	
	(n=19) (n=25)	(n=21) (n=25)	Circulation. 2019 Jan 15;139(3):337-346.

STEMI-DTU pilot trial

- U-DR group(Impella first) had smaller infarct size(estimated by CMR), higher EF, smaller EDV/ESV.
- U-DR group had equal CV mortality but higher major vascular events, thus higher MACCE.
- Differences are not significant maybe because of small study population.

Results	U-DR	U-IR	P Value	
30 days		10		
Infarct size, number assessed, n (%)	21 (84.0)	19 (76,0)		
Mean (±5D), %	13.1 (11.3)	15:3 (11:5)	0.53	
Median (IQR),%	10.4 (5.0-26.1)	13.0 (3.8-22.9)		
LVEF, number assessed, n (%)	21 (84.0)	19 (76.0)		
Mean (±SD), %	49.2 (12.9)	48,5 (13.4)	0.87	
Median (IQR), %	47.4 (39.4-61.0)	47.2 (35.9-59.9)		
LVESV, number assessed, n (%)	20 (80.0)	19 (76.0)		
Mean (±SD), mL	76.0 (43.9)	78.3 (34.4)	0.86	
Median ()QR), mL	69.0 (38.7-100.6)	65.5 (50.2-106.0)		
LVEDV, number assessed, n (%)	20 (80.0)	19 (76.0)		
Mean (±S0), ml.	140.9 (50.8)	147.9 (37.1)	0.63	
Median 0QR0, mL	147.8 (97.8-171.6)	149.6 (119.2-171.0)		


Table 4.	MACCE	at 30	Days
----------	-------	-------	------

	U-DR		U-IR			
Events	n⇒25	95% CI	n=25	95% CI	P Value	
MACCE, n (%)	3 (12)	2.55%-31.22%	2 (8)	0.98%-26.03%	0.99	
CV mortality, n (%)	1 (4)	0.10%-20.35%	1 (4)	0.10%20.35%	0.99	
Reinfarction, n (%)	0 (0)	0.00%-13.72%	0 (0)	0.00%-13.72%	-	
Stroke/TIA, n (%)	0 (0)	0.00%-13.72%	1 (4)	0.10%-20.35%	0.99	
Major vascular events, n (%)	2 (8)	0.98%-26.03%	0 (0)	0.00%-13.72%	0.49	

Circulation. 2019 Jan 15;139(3):337-346.

Results from Japanese registry

- impella alone (293 patients) vs ECMO+Impella (300 patients)
- Impella alone group showed better 30 days mortality rate(80.9% vs 45.7%)



(B) and ECPELLA (C) was 80.9% (95% Cl 75.9 – 84.9%) and 45.7% (95% Cl: 40.0–51.2%), respectively.

Circ J. 2023 Apr 25;87(5):588-597.

Evidence supporting superiority of IABP

- AMI with shock patients(retrospective study)
- Between 1680 matched pairs, Impella group had higher 30 days mortality and higher major bleeding.

Figure 2. In-Hospital Outcomes Among Propensity-Matched Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump

	Intravascular Microaxial Left Ventricular Assist Device		Intra-aortic Balloon Pump		Absolute Risk	Favors Intravascular Microaxial Left	Favors	
	No. of		No. of	second of test	Difference	Ventricular	Intra-aortic	
	Patients	Patients, %	Patients	Patients, %	(95% CI), %	Assist Device	Balloon Pump	P Value
Overall (n = 1680 matched pa	irs)							
Mortality	756	45.0	573	34.1	10.9 (7.6-14.2)			<.001
Major bleeding	526	31.3	268	16.0	15.4 (12.5-18.2)		-8-	<.001
Device placement before initi	ation of percutaneous	coronary interven	tion (n=573 m	natched pairs)				
Mortality	261	45.5	211	36.8	8.7 (3.1-14.4)			.003
Major bleeding	157	27.4	95	16.6	10.8 (6.1-15.6)			<.001
Device placement after initiat	ion of percutaneous c	oronary interventi	on (n = 662 mat	tched pairs)				
Mortality	291	44.0	213	32.2	11.8 (6.6-17.0)		9 	<.001
Major bleeding	228	34.4	104	15.7	18.7 (14.2-23.3)			- <.001

JAMA. 2020 Feb 25;323(8):734-745.

-15 -10 -5 0 5 10 15 20 25 Absolute Risk Difference (95% CI), %

Conclusion

- There are no clear criteria or evidence regarding the use of cardiac support devices during ACS treatment and which devices to use.
- Impella-based circulatory support is becoming the mainstay in cases of shock complications
- Impella requires caution because bleeding complications may define the life prognosis.
- IABP has difficulty demonstrating efficacy since the IABP-SOCK II trial, but has advantages in terms of relatively easier introduction, management, and rapidity of initiation, thus use with ACS is acceptable under certain circumstances.
- ECMO is essential in cases of right heart failure or respiratory failure even when using impella
- Further accumulation of basic and clinical findings is needed.